Sonoma Pharmaceuticals, Inc. (SNOA)
Data as of , from SEC Form 4 filings.
See up to 3 months of SNOA. The 7-day demo opens the 1M and 3M ranges and puts SNOA on your watchlist.
Start 7-day demoLatest SNOA insider trades
- Philippe Weigerstorfer - DirectorGrant or award10,000 sh
Amy Moss Trombly - OfficerGrant or award
About Sonoma Pharmaceuticals, Inc. (SNOA)
The SEC lists Sonoma Pharmaceuticals, Inc. under CIK 0001367083, in surgical and medical instruments and apparatus. It is grouped with Health Care companies on this site. A registration statement was filed on 17 April 2026. No offering has priced.
SNOA Form 4 activity by transaction type, last 90 days
No Form 4 activity for SNOA in the last 90 days.
SNOA insider transactions (Form 4)
1212 Form 4 filings on record, the earliest from Jan 2, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Philippe Weigerstorfer - Director | Grant or award | Stock option (right to buy) | 10,000 | - footnote F2 | - | |
| ||||||
| Amy Moss Trombly - Officer | Grant or award | Restricted Stock Units | 10,000 | $0.00 footnote F1,F3 | - | |
| ||||||
 John McLaughlin - Director | Grant or award | Stock option (right to buy) | 10,000 | - footnote F2 | - | |
| ||||||
| Vanessa Jacoby - Director | Grant or award | Stock option (right to buy) | 10,000 | - footnote F2 | - | |
| ||||||
| Jerome J. Dvonch - Officer | Grant or award | Restricted Stock Units | 10,000 | $0.00 footnote F1,F3 | - | |
| ||||||
 Poggetto John Dal - Officer | Grant or award | Restricted Stock Units | 7,500 | $0.00 footnote F1,F3 | - | |
| ||||||
| Philippe Weigerstorfer - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Amy Moss Trombly - Officer | Grant or award | Restricted Stock Units | 10,000 | $0.00 | - | |
| John McLaughlin - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
| Jerome J. Dvonch - Officer | Grant or award | Restricted Stock Units | 5,000 | $0.00 | - | |
| Poggetto John Dal - Officer | Grant or award | Restricted Stock Units | 5,000 | $0.00 | - | |
| Jay E. Birnbaum - Director | Grant or award | Stock option (right to buy) | 10,000 | - | - | |
SNOA insider trading FAQ
What is the latest insider trade for SNOA?
Sonoma Pharmaceuticals, Inc. (SNOA) has filed no insider reports in the last 90 days. The most recent on record is dated 10 July 2026. The full record for SNOA runs to 12 Form 4 filings, the earliest from 2 January 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SNOA stock?
No insider purchases of SNOA were filed in the last 90 days.
How many insiders are selling SNOA stock?
No insider sales of SNOA were filed in the last 90 days.
Where can I see SNOA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SNOA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Philippe Weigerstorfer view on EDGAR
- - Amy Moss Trombly view on EDGAR
- - John McLaughlin view on EDGAR
- - Vanessa Jacoby view on EDGAR
- - Jerome J. Dvonch view on EDGAR
- - Poggetto John Dal view on EDGAR
- - Philippe Weigerstorfer view on EDGAR
- - Amy Moss Trombly view on EDGAR
- - John McLaughlin view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where SNOA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SNOA with a 7-day demo
- SNOA on your watchlist
- Every SNOA Form 4 filing on record
- Up to 3 months of SNOA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
